Expression of the JCV early protein T-antigen in transgenic mice leads to the development of cerebellar primitive neuroectodermal tumors (PNETs). In light of earlier reports on the association of JCV with PNETs in humans and the involvement of the Wnt signaling pathway in the development of cerebellar tumors, we investigated the interplay between T-antigen and bcatenin, the key protein of the Wnt pathway. Our results demonstrate the physical interaction of T-antigen with bcatenin through the central domain of T-antigen spanning residues 82-628, and the C-terminus of b-catenin located between amino acids 695 and 781. The association of Tantigen with b-catenin elevates the level of b-catenin in the cells due to increased in the stability of the protein. In the presence of T-antigen, b-catenin was found in the nuclei of cells, suggesting that the interaction of b-catenin with T-antigen facilitates its nuclear import. In cells expressing mutant T-antigen with no nuclear localization domain, b-catenin was found in the cytoplasm. Coexpression of T-antigen with b-catenin increased the transcription of the c-myc promoter, a known downstream target of b-catenin, and artificial promoter whose activity is bcatenin dependent. These observations ascribe a new oncogenic pathway for T-antigen, and offer an alternative mechanism for the deregulation of the Wnt pathway through stabilization of b-catenin upon its association with the viral oncoprotein.
Introduction
The Wnt pathway is important in tissue development, due to its control of cell proliferation, polarity, and fate. When the Wnt pathway is silent, b-catenin, the bifunctional protein of the Wnt pathway, binds to the cell surface protein E-cadherin, which functions as an adherence junction protein for cell-cell contact (Cadigan and Nusse, 1997) . At this stage, a cell strongly controls its b-catenin concentration by using the adenomatous polyposis coli APC, which binds to excess amounts of b-catenin. This interaction promotes phosphorylation of b-catenin via its N-terminus by CK1 and GSK-3b (Polakis, 2000; Gao et al., 2002) . The phosphorylated b-catenin, in turn, undergoes degradation by the ubiquitin-mediated pathway (Polakis, 2000) .
Activation of the Wnt pathway occurs upon binding of the secreted Wnt glycoprotein to the frizzled cell surface receptor. Under these circumstances, the APC degradation pathway shuts down, and hypophosphorylated b-catenin, in association with the family of LEF-1/ TCF-4 transcription factors, translocates into the nucleus, where it augments the expression of cell growth-stimulating genes such as c-myc and cyclin D1 (He et al., 1998; Shtutman et al., 1999) . Mutations of Wnt factors have been linked to several types of cancers (Morin, 1999) . For example, a mutation on the APC gene in colon cancer cells results in cells losing control of the b-catenin degradation pathway, and the accumulation and nuclear appearance of b-catenin (Polakis, 2000) . A mutation of b-catenin at the phosphorylation site can also result in stabilization of the protein that would normally translocate into the nucleus and activate its downstream genes (Morin, 1999) . Earlier studies have revealed a mutation in b-catenin in human medulloblastomas (Eberhart et al., 2000) , the most common pediatric intracranial tumors with a peak of occurrence between the ages of 7 and 10 years. The causative agents of the tumor, which arises from the external granular cells of the cerebellum, remain unknown. However, several recent studies have pointed to the involvement of the hedgehog and the Wnt pathway in this event (Eberhart et al., 2000; Weiner et al., 2002) . In addition, recent studies have revealed the association of the human neurotropic polyomavirus JCV with medulloblastomas (Krynska et al., 1999a; Del Valle et al., 2001a, b) . JCV is a ubiquitous virus infecting greater than 70% of the human population prior to 14 years of age and remaining in a latent stage during life (Walker and Padgett, 1983; Agostini et al., 2001) . Dysfunction of the immune system due to a variety of reasons can result in reactivation of the latent viral genome and its replication in astrocytes and oligodendrocytes, which leads to the development of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) (for a review see Berger and Concha, 1995; Berger and Major, 1999) . Similar to other polyomaviruses, the early protein of JCV, T-antigen, plays a pivotal role in initiating viral replication. Further, Tantigen is an oncogenic protein with the ability to transform cells in vitro (Del Valle et al., 2001a ; for a review see Gallia et al., 1998) . In earlier studies to unravel the biological function of JCV T-antigen, we created transgenic animals expressing the JCV early protein via the viral early promoter. Several lines developed tumors in the cerebellum, which were classified as medulloblastomas based on the location and expression of marker proteins (Krynska et al., 1999b) . The expression of T-antigen was detected in tumor mass, and in cell lines derived from the tumor (Krynska et al., 2000) . In our earlier studies, we demonstrated an elevated level of b-catenin and its nuclear import in the cells expressing T-antigen (Gan et al., 2001) . In this study, we utilized a wellcharacterized cell line, BSB8, from the JCV-T mouse medulloblastoma, and human astrocytoma cells, U-87MG, to investigate the mechanism of T-antigeninduced dysregulation of the Wnt pathway by focusing on the interplay between T-antigen and b-catenin. Our results demonstrate the physical interaction of JCV Tantigen with wild-type b-catenin that may lead to its stabilization, nuclear import, and stimulation of c-myc; events which are seen upon dysregulation of Wnt through mutation in b-catenin in human medulloblastoma.
Results
In the first series of experiments, we assessed the association of JCV T-antigen with b-catenin in a mouse medulloblastoma cell line, BSB8, that expresses Tantigen (Krynska et al., 2000) . The protein extract from BSB8 was incubated with anti-T-antigen antibody or normal serum, and the immunocomplexes were analysed by Western blot using an anti-b-catenin antibody. As illustrated in Figure 1 (Panel a, top), a band corresponding to b-catenin appeared when the BSB8 protein extract reacted with anti-T-antigen antibody, but not with the normal serum. The presence of T-antigen in the immunocomplexes is shown by Western blot using anti-T-antigen antibody (Figure 1, Panel a, bottom) . In a reciprocal experiment, immunocomplexes precipitated by anti-b-catenin or normal serum were tested by Western blot using anti-T-antigen antibody. Detection of T-antigen in the b-catenin immunocomplex points to the association of T-antigen with b-catenin in the protein extract from BSB8 cells (Figure 1, Panel b, top) . From the intensity of the band corresponding to Tantigen, it appears that only a portion of T-antigen is associated with b-catenin (Figure 1b , top, compare lane 3 with lane 1). It is possible that other well-known cellular proteins such as p53 and pRb also associate with T-antigen in these tumor cells. A similar set of experiments was carried out to determine the association of T-antigen with LEF-1, and the results showed a strong interaction between the two (data not shown). To further establish the specificity of b-catenin and Tantigen interaction, a series of deletion mutants of Tantigen were used in GST pull-down assays. The results demonstrated that while the N-and C-termini of Tantigen spanning the residues between 1-81 and 629-688, respectively, exhibit no binding activity with bcatenin, the minimal region spanning residues 412 and 688 possesses a strong binding affinity to b-catenin (Figure 2b) . A weak yet noticeable binding of b-catenin to mutant T-antigen 1-265 and 1-411 was also observed (Figure 2b ). T 1-628 has a stronger binding ability to bcatenin compared to full-length T-antigen, which may imply that the C-terminal tail of T-antigen has a negative effect on this protein-protein interaction, perhaps through the formation of a secondary structure.
In a converse set of experiments, the region within bcatenin, which is important for its association with Tantigen, was determined. As illustrated in Figure 3a , b-catenin can be divided into three functional domains; the N-terminus (residues 1-132) that confers stability to the protein, the central region (residues 132-695) that interacts with several proteins including its partners, LEF-1 and TCF-4, and the C-terminus (residues 695-781) known as the transcriptional activation domain. Two mutants of b-catenin with a deletion in residues 1-132 (DN b-catenin) and a deletion between amino acids 695 and 781 (DC b-catenin) were constructed, and their ability to bind to T-antigen was evaluated. As shown in Figure 3b , while both mutant proteins were produced in the cells transfected with plasmids expressing the bcatenin mutants, only DN b-catenin was able to associate with T-antigen, suggesting that the residues between 695 and 781 are essential for formation of the T-antigen : b-catenin complex.
In light of the previous observations showing elevated levels of b-catenin in T-antigen-positive murine medulloblastomas compared to its level in the Tantigen-negative cells (Gan et al., 2001) , and the current data on the binding of T-antigen to b-catenin, the stability of b-catenin in the presence of T-antigen was determined. In the first attempt, human astrocytoma cells, U-87MG, were transfected with plasmids expressing full-length b-catenin either alone or together with a plasmid that expresses JCV T-antigen. A similar transfection was carried out with plasmids expressing DN b-catenin or DC b-catenin mutants. Protein extracts from the transfected cells were analysed by Western blot. All expression constructs contain the same background plasmid with the common promoter derived from cytomegalovirus early gene. As shown in Figure 4 , expression of T-antigen enhanced the level of full-length b-catenin and mutant DN b-catenin, both of which possess the ability to associate with T-antigen. The level of DC b-catenin, which exhibited no binding capacity to T-antigen, remained unchanged in the presence of Tantigen. It is possible that the stability of the C-terminal deletion mutant of b-catenin in the absence of T-antigen is caused by the association of cellular proteins with the N-terminal region of the protein, which was assumed to play a role in the stability of the protein. Alternatively, it is possible that the removal of the C-terminus of bcatenin brings a new configuration to the protein that becomes more resistant for degradation. These observations suggest that the interaction of T-antigen with bcatenin may increase the stability of b-catenin.
In the second set of experiments, protein extracts from U-87MG were mixed with bacterially produced JCV T-antigen fused to glutathione-S-transferase (GST-T-antigen); mutant T 1-81 , which exhibits no binding activity to b-catenin; or the control GST, and the mixture was treated with trypsin for various time periods prior to analysis by Western blot. As illustrated in Figure 5 It is believed that stabilization of b-catenin is governed by either mutation in its gene or its association with its cellular partner, resulting in nuclear import of the protein. As such, in the next series of experiments, we determined whether expression of T-antigen alters the subcellular localization of b-catenin. The experiment was performed by transfection of U-87MG cells with plasmids expressing full-length T-antigen or its mutant variants such as T 1-265 , and its counterpart with no nuclear localization domain, T 1-265DNLS . Examination of T-antigen and the endogenous b-catenin in the cells was performed by immunofluorescent staining. Figure 6 illustrates phase (top row) and fluorescence microscopy (bottom rows) of the cells primed for detection of either T-antigen or b-catenin, and T-antigen plus b-catenin. In cultures transfected with full-length T-antigen, we selected a field depicting two cells in which only one received T-antigen plasmid and expresses T-antigen. In cells expressing T-antigen, the level of b-catenin is higher, and is localized in the nucleus along with Tantigen. In T-antigen-negative cells, b-catenin remains in the cytoplasm, at a lower level. Similar results were obtained with mutant T 1-265 in which expression of Tantigen was found in the cells where b-catenin was imported to the nucleus. Interestingly, in cells expressing T 1-265DNLS , where T-antigen is localized in the cytoplasm, b-catenin was also found in the cytoplasm. These observations suggest that association of b-catenin and T-antigen leads to nuclear entry of b-catenin, where it can exert its regulatory action upon responsive genes.
Functionally, the expression of b-catenin and Tantigen elevated the transcription of the c-myc promoter in U-87MG cells (Figure 7a ). Mutant T 1-81 failed to cooperate with b-catenin in stimulating the transcription 
Discussion
Cell lines derived from JCV-induced medulloblastomas in transgenic mice can be divided into two groups based on their level of T-antigen expression (Krynska et al., 2000) . In both groups, however, several known regulatory pathways are dysregulated due to inactivation of the major tumor-suppressor proteins such as p53, either through its association with T-antigen in T-antigenpositive cells or a mutation in the p53 gene in T-antigennegative cells (Krynska et al., 2000) . Nevertheless, results from cell proliferation and nude mice studies revealed that T-antigen cells replicated faster in vitro, and induce larger tumors in flanks of nude mice than those from the T-antigen-negative cells. These observations suggest the involvement of other regulatory events by T-antigen, which may contribute to the pathogenesis of JCV-associated medulloblastomas. One of the pathways that was implicated in the development of human medulloblastomas is the Wnt signaling pathway, whose key protein b-catenin was found to be stabilized upon mutation and localized in the nuclei of several clinical samples (Eberhart et al., 2000) . As the higher level of bcatenin in our murine cell culture models may not be entirely attributed to transcriptional activation of the bcatenin gene by T-antigen, we tested the potential of Tantigen association with b-catenin, which, in turn, may enhance the stability of the protein in the cells. In fact, our results showed that JCV T-antigen binds to bcatenin through its transcriptional activation domain, and this interaction may stabilize b-catenin. In this respect, stabilization of b-catenin may occur in the following ways: (i) JCV T-antigen bound to the Cterminal of b-catenin peptide forms a structural barrier to prevent APC, CK1, and GSK-3b from binding to and phosphorylating the N-terminus of b-catenin, an event that promotes b-catenin ubiquitination (Polakis, 2000; Gao et al., 2002) ; (ii) interaction of JCV T-antigen with APC that can inhibit its activity by blocking the association of APC with b-catenin for the degradation complex; (iii) T-antigen-induced downregulation or inhibition of the activity of GSK-3b and CK1 by Tantigen, so that GSK-3b and CK1 may not phosphorylate b-catenin for the degradation process; and (iv) translocation of the JCV T-antigen : b-catenin complex into the nucleus, so that b-catenin will not be degraded in the cytoplasm. At present, our data indirectly favor a role for T-antigen in blocking b-catenin from degradation, and nuclear import of b-catenin through the association with T-antigen. Our results from immunofluorescence experiments of mutant T 1-265DNLS show that when b-catenin is colocalized with this mutant in the cytoplasm, the level of b-catenin appears to be higher than that which is detected in the cytoplasm of Tantigen-negative cells. Thus, the N-terminal region of the JCV T-antigen, which associates with b-catenin, may prevent the interaction between APC, CK1, or GSK-3b to b-catenin. Recent studies on the structure and function of the N-terminus and C-terminus of b-catenin indicate that these two domains are interconnected, and differently regulate their binding to the center armadillo domain (Castano et al., 2002) . Thus, it is likely that binding of JCV T-antigen to the C-terminal of b-catenin forms a steric hinder effect to the N-terminal domain of b-catenin, and protects the protein from associating with the degradation complex. Our data also show that JCV T-antigen can stabilize DN b-catenin, but not DC b-catenin. This observation further supports the notion that the interaction between JCV T-antigen and b-catenin is important for the stabilization of b-catenin. As DN b-catenin has no Nterminal domain, the known target for phosphorylation and degradation by ubiquitin pathways, one may question how JCV T-antigen results in its stabilization of the protein by associating with mutant b-catenin. According to one model, T-antigen may facilitate nuclear import of DN b-catenin, and hence prevent its ubiquitination in the cytoplasm. Alternatively, in the cytoplasm, T-antigen may prevent DN b-catenin degradation through an APC-independent pathway. In this regard, one may consider a role for p53, which under certain conditions can regulate a Siah/Ebi degradation complex through the p21 WAF-1 pathway and degrade bcatenin (Polakis, 2001 ). The association of T-antigen with p53 may neutralize this event and indirectly protect DN b-catenin protein against proteolytic degradation. Functionally, we demonstrated that b-catenin and Tantigen cooperate to elevate transcription of the c-myc promoter. Whether or not the observed cooperation of b-catenin with T-antigen requires LEF-1 or TCF-4 remains to be investigated. Our preliminary data suggest that T-antigen also forms a complex with LEF-1. Thus, one may postulate that T-antigen, by forming a heteromeric complex with b-catenin and LEF-1, increases their transcriptional activity. Alternatively, it is possible that the interaction of T-antigen with b-catenin and LEF-1 becomes mutually exclusive. In support of this notion, results from GST pull-down assays with LEF-1 and b-catenin revealed a common domain within T-antigen for binding of these two cellular proteins. As such, intracellular concentration of these proteins and their affinity for binding to each other may dictate the ratio of T-antigen interaction with b-catenin and LEF-1. Communication between the Wnt-b-catenin pathway and viruses has been suspected in recent years. According to the most recent studies, the ability of Kaposi's sarcoma-associated herpesvirus (KSHV) LANA protein to relocalize GSK-3b into the nucleus leads to cytoplasmic depletion of GSK-3b and higher levels of bcatenin in the nucleus (Fujimuro et al., 2003) . Currently, studies are in progress in our laboratory to further decipher the mechanism whereby T-antigen, b-catenin, and LEF-1 are involved in the development of cerebellar tumors in experimental animals and in tumor cells with a distinct pattern of cell proliferation.
Materials and methods

Cell lines
The mouse medulloblastoma cell line BSB8 (Krynska et al., 2000) , the JCV-induced hamster astrocytoma cell line HJC2 (Raj et al., 1995) , and the human astrocytoma U-87MG cell line (ATCC, Bethesda, MD, USA) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and incubated at 371C in a humidified atmosphere with 7% CO 2 .
Plasmids
The plasmid pcDNA3-JCT was created by placing a DNA fragment corresponding to the JCV early genome (without intron) into the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA). All other constructs containing JCV T-antigen mutants, that is, T 1-265 , T 1-265DNLS , and T 1-81 , were created with PCRgenerated fragments, using a JCV early-genome template in a pcDNA6/Myc-His version B background (Invitrogen). All GST-T-antigen constructs have been described previously (Safak et al., 2001) . The pCS2MT4145 b-catenin was obtained from Dr Franc¸ois Fagotto (Xu et al., 2000) . The pEVRF-T7-WT b-catenin, pEVRF-T7-DN b-catenin, and pEVRF-T7-DC b-catenin were kindly provided by Dr Rudolf Grosschedl (Hsu et al., 1998) . The pDel-1 was kindly provided by Dr Bert Vogelstein (He et al., 1998) . Dr Ramin Shiekhattar, of the Wistar Institute, kindly provided the luciferase reporter constructs, TOPflash and FOPflash. TOPflash contains three TCF-binding sites and the minimum promoter from the c-Fos gene. FOPflash contains the mutated version of the TCFbinding site with the minimum c-Fos promoter sequence (Korinek et al., 1997) .
Coimmunoprecipitation and direct Western blot
Whole-cell lysates were prepared according to the procedures previously described (Gan et al., 2001) . Briefly, cells were lysed in TNN buffer (50 mm Tris, pH 7.5; 150 mm NaCl; 0.5% NP-40) containing the protease inhibitor cocktail (Sigma, St Louis, MO, USA). After centrifugation to remove cell debris, the supernatants containing cell lysates were either incubated with the preimmune sera (NMS), the anti-T-antigen antibody (clone pAb416, Oncogene Science, Boston, MA, USA), or the anti-bcatenin antibody (clone E-5, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The immunocomplexes were separated by SDS-PAGE, transferred to PVDF membranes, and analysed by Western blot using either the anti-T-antigen antibody, the anti-b-catenin antibody, or the anti-T7 tag antibody (Novagen, Darmstadt, Germany). For direct Western blot, 50 mg of cell lysates were analysed by SDS-PAGE and transferred to PVDF membranes. The membranes were incubated with either the anti-T-antigen antibody, the anti-b-catenin antibody, the anti-T7 tag antibody, or the anti-Grb-2 antibody (clone 81; BD Transduction Laboratories, San Diego, CA, USA). For detection, blots were incubated with horseradish peroxidaseconjugated secondary antibodies, and an ECL-plus detection kit was used in the last step, according to the manufacturer's recommendations (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
GST pull-down assay
Production of GST or GST fusion proteins was carried out in E. coli BL21 grown in LB-broth containing 0.3 mm isopropyl b-d-1-thiogalactopyranoside (IPTG) for 3 h at 371C. The cells were lysed by sonication in STE buffer (10 mm Tris, pH 8.0; 150 mm NaCl, 1 mm EDTA) with 10% lysozyme, 5 mm DTT, 1% sarcosyl, and protease inhibitor cocktail. The lysate was centrifuged, and the clear supernatant was incubated with GST beads for 1 h. The mixture was washed three times with PBS, after which the beads were kept in storage buffer (50 mm HEPES, pH 7.4; 150 mm NaCl; 5 mm DTT, 10% glycerol, protease inhibitor cocktail). For GST pull-down assay, 10 mg of GST, GST-T-antigen, or its deletion mutants were immobilized on sepharose beads, and incubated with 300 mg of whole-cell extract for 2 h at 41C in a lysis buffer containing 50 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.5% NP-40, and protease inhibitor cocktail. The mixture was extensively washed with the lysis buffer, and the proteins were resolved by 10% SDS-PAGE, followed by Western blot analysis using the anti-myc tag antibody (version E, Invitrogen). Trypsin digestion experiment U-87MG cells were lysed in TNN buffer (50 mm Tris, pH 7.5; 150 mm NaCl, and 0.5% NP-40). A volume of 5 fmol of GST, GST-T-antigen, or GST-T 1-81 in trypsin buffer (90 mm TrisHCl, pH 8.0; 2 mm CaCl 2 ; 4 mm DTT) was mixed with 12 mg of cell lysates for 5 min at room temperature. Trypsin (1 ng; Sigma) was added to each reaction mixture, and incubated as indicated in each experiment at room temperature. The reaction was stopped by the addition of Laemmli's buffer, and boiled for 10 min prior to analysis by Western blot.
The alternative approach was carried out by using 11 mg of cell lysates from U-87MG transfected with either T-antigen, T 1-265 , or T 1-81 , which were incubated with 1 ng of trypsin in trypsin buffer for the desired times. The reaction was stopped and analysed by Western blot.
Immunofluorescence assay U-87MG cells were transfected with various T-antigenexpressing plasmids, and, after 40 h, washed with PBS, fixed in cold acetone, and blocked in PBS containing 5% horse serum and 0.1% BSA for 2 h. Following that, they were incubated with either mouse anti-T-antigen antibody (clone pAb416, 1 : 100 dilution; Oncogene Science), for detecting fulllength T-antigen, or the mouse anti-His (C-term) antibody (version E, 1 : 250 dilution; Invitrogen) for detecting T 1-265 and T 1-265DNLS . After 16 h incubation, the cells were washed with PBS and incubated with the anti-mouse fluorescein antibody (1 : 200 dilution, Vector Laboratories, Burlingame, CA, USA). After 2 h, they were washed with PBS before being incubated with the mouse anti-b-catenin antibody (clone E-5, 1 : 100 dilution, Santa Cruz Biotechnology). After 16 h incubation, they were washed with PBS and incubated with the anti-mouse Texas-red antibody (Vector Laboratories, 1 : 200 dilution) for 2 h. Finally, the cells were washed with PBS and mounted in aqueous mounting media (Vector Laboratories) and examined under microscope.
Luciferase assay
U-87MG cells were synchronized by serum starvation for 48 h, followed by 12 h serum stimulation before transfection. Cells were transfected by the calcium phosphate precipitation method with 3 mg of reporter constructs alone, or in combination with different expression plasmids, as indicated in each experiment. The total amount of DNA in each transfection reaction was normalized with the relevant empty vector DNA. At 18 h post-transfection, the cells were harvested and lysed with Cell Culture Lysis 1 Â Reagent (Promega, Madison, WI, USA), and 20 ml of concentration-normalized protein extract from each sample was mixed with 100 ml of Luciferase Assay Reagent (Promega); luciferase activity was detected by a luminometer. Each transfection was triplicated, and the standard deviation was indicated.
